Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplant for Postoperative Crohn's Disease
NCT05248191Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Crohn's disease comparing Capsule FMT (cap-FMT) with Colonoscopic FMT (colo-FMT) + Placebo (2 arms). Primary endpoint: Ileal-associated microbiota engraftment at 8 weeks. Started Apr 2022; status: completed.
02
Drugs
Fecal Microbiota Transplantation capsules
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05248191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248191.